Ipca is the 1
st company in the world with whom the Clinton Foundation has signed a
partnership agreement for supply of Artesunate 50mg + Amodiaquine 153.1mg Co-blister
tablets at a reduced price to the Clinton Foundation Consortium to ensure wider access. It
has also signed an agreement for supply of Artemether 20mg + Lumefantrine 120mg
Tablets.
Ipca’s Managing Director, Mr. Premchand Godha and VP International – Strategic
Business Development & Head – Mission Malaria, Mr. Murali Sarma were invited to the
Clinton Foundation office in New York for the official announcement of the partnership
agreement on 17th July 2008, which got an excellent coverage on TV & in the press in
USA as well as other countries including India.
In his speech Mr. Godha mentioned, “As one of the largest manufacturers of anti malarial
Active Pharmaceutical Ingredients and Formulations worldwide, and with over 30% of
the Indian anti malarial market, we are proud to partner with the Clinton Foundation in
providing affordable and effective treatment for malaria. Ipca has been supplying anti
malarial medicines for over thirty years and treating malaria has been a personal mission
of mine and my company. Ipca has also been spearheading its own efforts under the
initiative of “Mission Malaria” with the sole objective of helping treat and save millions
of lives.”
Former president Bill Clinton, announced agreements with Six companies – Ipca
Laboratories & Cipla (2 Formulations manufacturers) Calyx & Mangalam Drugs (2 APIs
manufacturers) Holleypharm & PIDI – China (2 Artemisinin Manufacturers).
